OTC:ADAPY | Free Cash Flow | Adaptimmune Therapeutics PLC

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2014-06-30 to 2025-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-03-31-$66.59M$1.2M-$67.8M
2024-12-31-$34.2M$219,000.00-$34.42M
2024-03-31-$31.95M$102,000.00-$32.05M
2023-12-31-$14.68M$827,000.00-$15.5M
2023-03-31-$37.28M$2.35M-$39.63M-3825.48%
2022-12-31$2.04M$3.42M-$1.37M
2022-03-31-$54.4M$7.11M-$61.52M
2021-12-31$133.93M$4.02M$129.91M
2021-03-31-$46.54M$1.15M-$47.69M
2020-12-31-$29.22M$1.17M-$30.38M
2020-03-31$16.86M$192,000.00$16.67M
2019-12-31-$12.53M$167,000.00-$12.7M
2019-03-31-$36.2M$904,000.00-$37.11M
2018-12-31-$31.69M$87,000.00-$31.77M
2018-03-31-$47.28M$1.9M-$49.18M
2017-12-31-$21.36M$1.85M-$23.21M
2017-03-31-$28.44M$12.25M-$40.69M
2016-12-31$2.37M$6.67M-$4.3M
2016-03-31-$18.68M$1.71M-$20.39M
2015-03-31-$5.64M$672,000.00-$6.32M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2024-12-31-$73.21M$886,000.00-$74.09M
2023-12-31-$140.88M$4.68M-$145.56M
2022-12-31-$141.77M$29.5M-$171.27M
2021-12-31$10.73M$8.57M$2.16M
2020-12-31-$53.59M$2.34M-$55.93M
2019-12-31-$112.51M$1.59M-$114.1M
2018-12-31-$104.39M$3.91M-$108.3M
2017-12-31-$54.32M$24.64M-$78.96M
2016-12-31-$48.17M$11.51M-$59.67M
2015-06-30-$29.67M$5.08M-$34.75M
2014-06-30$36.84M$1.37M$35.47M